Orchestra BioMed Holdings Inc.: Piper Sandler raises target price to $12 from $10
OBIO•Piper Sandler raised its target price for Orchestra BioMed Holdings to $12 from $10.
Related News
DoubleLine Yield Opportunities Fund declares October distribution of $0.1167 per share
DLY•
Nebius Group director John Wilson Boynton IV sells 50 common shares for $11,750.50
NBIS•
Quanome enters revolving loan agreement with CEO for up to $15 million at 6% interest
QNME•
U.S. Bank freight index shows dry van contract rates rise as spot rates cool
USB•
Apimeds Pharmaceuticals appoints Eric Sherb as CFO effective Oct. 1
APUS•